Research Snapshot: Researchers Identify Genes That Predict Pediatric AML Outcomes
UF Health researchers have used a promising approach by integrating CRISPR-cas9-based drug screening with patients’ clinical outcome to identify genes and pathways that predict how patients will respond to the standard firstline chemotherapy treatment regimen used to treat patients with acute myeloid leukemia, or AML.
Led by Jatinder Lamba, Ph.D., co-leader of the UF Health Cancer Center’s Cancer Targeting and Therapeutics research program, the team identified genes that were associated with resistance or sensitivity to chemotherapy and linked these with patients’ treatment outcomes. The findings, published recently in the American Society of Hematology’s journal Blood Advances, could help develop new treatments to overcome resistance to chemotherapy.
Read more about Research Snapshot: Researchers Identify Genes That Predict Pediatric AML Outcomes.Learn more about technologies discovered by Jatinder Lamba.